Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-C1 PET/CT in Clear Cell Renal Cell Carcinoma
NCT06519760Recruiting
- Sponsor
- Peking University First Hospital
- Start
- Jul 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of 68Ga-C1 in clear cell renal cell carcinoma (ccRCC), sponsored by Peking University First Hospital. Primary endpoints: The diagnostic efficacy of 68Ga-C1 PET/CT in the evaluation of clear cell renal cell carcinoma at 1 year and The diagnostic efficacy of 68Ga-C1 PET/CT in the evaluation of malignant tumors at 1 year. Started Jul 2024; status: recruiting.
02
Drugs
68Ga-C1
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT06519760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06519760.